10 Apr. 2019
WHO CALLS FOR URGENT ACTION TO END TB
WHO’s 2018 Global TB Report, released in New York today, calls for an unprecedented mobilization of national and international commitments. It urges p...
10 Apr. 2019
3SAT MEDIATHEK
An interesting and informative report on bacteria and antibiotic resistance including an interview with Marc Gitzinger. The report starts at 10.25 htt...
10 Apr. 2019
SPIEGEL ONLINE: MEHR ANTIBIOTIKARESISTENTE KEIME - SCHWERERE THERAPIE
Entwickeln Bakterien Resistenzen gegen Antibiotika, werden eigentlich gut behandelbare Krankheiten gefährlich. In Deutschland stoßen Experten immer öf...
10 Apr. 2019
BIOVERSYS AND INSTITUT PASTEUR DE LILLE WORKING TOGETHER
BioVersys AG s’implante à Lille pour intensifier la recherche et le développement de nouveaux hashtag#antibiotiques afin de combattre la résistance ba...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
